Q: Looking at one/both of these for a TFSA. Could you comment on their competitive advantage - if any. Other issues that would concern you ? If you were to put a 5i rating on them for the Growth Portfolio, can you take a stab at what that might be ?
The 3 smallest positions in my TFSA are MCR, PHO, and LSPD, (I also hold a full position in Shop) . Would increasing those be preferable ?
Q: Bought this stock some time ago @ $1.25 and now $2.40 It has had a progressive positive climb. Thoughts about this company"s future?
Thank for your review!
Q: Hi 5i Team,
Would you add to existing positions in these two stocks or wait for a pull back?
Which one would you add to first at today's prices?
Thanks!
Q: More a comment than a question, I just read your answer to a question asked by David. My understanding of Sangoma current cash and debt position is the following : on July 16, 2019, Sangoma closed a short-form bought deal prospectus offering of 14,846,500 common shares, at a price of $1.55 per common share for aggregate gross proceeds of $23,012,075. As of June 30, 2019, Sangoma had $11,724,000 in cash, therefore, it is fair to say that on July 16 Sangoma had ±$34,700,000 in cash ($23,012,075 + $11,724,000).
Following the acquisition of VoIP Innovations, Sangoma has drawn approximately C$46 million from a credit line provided by BMO and TD. Approximately CDN$22 million will be used to pay off all existing debt and around CDN$24 million to fund this acquisition. Since the acquisition is for US36,000,000 or ±CDN$48,000,000, Sangoma will withdraw CDN$24,000,000 from its cash reserve leaving approximately CDN$10,7000,000 in cash and will be have a debt of CDN$46 million.
Q: Any thoughts why Sangoma still trades less than 1X revenues (on forward guidance) despite having almost half of its revenues recurring. The Company has grown a lot and Management has a history of making good acquisitions. Do you think the stock is due for a re-rating more inline with its peers?
Q: What is 5i's opinion of Sangoma's Q4 and fiscal 2019 results and the major acquisition just announced? With the acquisition Sangoma's recurring revenues is 45% of total sales. You it be fair that a Company of this size now trade at a sales multiple greater than 1 when a good portion of revenues are recurring?
Q: Is 5i considering a closer look at Sangoma Technologies for their growth portfolio and/or research coverage? The Company's management is consistently beating analyst estimates and the market cap is now over $100 million with a lot of value given the 4 analyst estimates going forward.
Q: Hi guys! I asked this question a few days ago and received no reply. Not sure what happened, it could have been on my end. I have equal portions of these 8 stocks in my TFSA. What do you think of these stock selections?
Thank You !
Q: What is 5i's thoughts about Sangoma's bought deal financing announced this morning at $1.55. Despite the dilution is it good for current shareholders given the Company's track record? Will it improve valuation metrics (trading multiples) going forward? Currently Sangoma trades less then 1X sales which seems very cheap against their peer group and other small caps.